Rigel’s Tavalisse Hits Pothole In Label Expansion For Hemolytic Anemia

Tavalisse misses the primary endpoint in a 90-patient Phase III trial in warm autoimmune hemolytic anemia, but Rigel contends a high placebo response in Eastern Europe confounded the results.